Oral fibrinogen-depleting agent lumbrokinase for secondary ischemic stroke prevention： results from a multicenter, randomized, parallel- group and controlled clinical trial

Oral fibrinogen-depleting agent lumbrokinase for secondary ischemic stroke prevention： results from a multicenter, randomized, parallel- group and controlled clinical trial

Background Elevated fibrinogen （Fg） level is a known risk factor for ischemic stroke. There are few clinical trials on oral fibrinogen-depleting therapies for secondary ischemic stroke prevention. We aimed to assess the effects of one-year therapy with oral lumbrokinase enteric-coated capsules on se...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Chinese medical journal 2013-11, Vol.126 (21), p.4060-4065
Hauptverfasser: Cao, Yong-Jun, Zhang, Xia, Wang, Wan-Hua, Zhai, Wan-Qing, Qian, Ju-Fen, Wang, Jian-Sheng, Chen, Jun, You, Nian-Xing, Zhao, Zhong, Wu, Qiu-Yi, Xu, Yuan, Yuan, Lei, Li, Rui-Xia, Liu, Chun-Feng
Format: Artikel
Sprache:eng
Schlagworte:
Administration, Oral
Aged
Carotid Intima-Media Thickness
Endopeptidases - administration & dosage
Endopeptidases - therapeutic use
Female
Fibrinogen - metabolism
Humans
Male
Middle Aged
Secondary Prevention
Stroke - prevention & control
临床试验
二级
多中心
消耗
纤维蛋白原
缺血
蚓激酶
预防
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Elevated fibrinogen （Fg） level is a known risk factor for ischemic stroke. There are few clinical trials on oral fibrinogen-depleting therapies for secondary ischemic stroke prevention. We aimed to assess the effects of one-year therapy with oral lumbrokinase enteric-coated capsules on secondary ischemic stroke prevention.
ISSN:0366-6999
2542-5641
DOI:10.3760/cma.j.issn.0366-6999.20131332